Drug Database
Back to search

Netherlands· NL-0ba8ad4b5828

Opzelura 15 mg/g crème

A ruxolitinib product containing ruxolitinibfosfaat, registered in Netherlands by Incyte Biosciences Distribution B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC D11AH09

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOpzelura 15 mg/g crèmeATCD11AH09REGISTER NO.NL-0ba8ad4b5828PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ruxolitinibfosfaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ruxolitinib is registered in 14 of 19 countries.

Countries holding a registration under ATC D11AH09 (ruxolitinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search ruxolitinib products by name

Ruxolitinib · ATC D11AH09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
RUXOLITINIBFOSFAAT
Manufacturer
Incyte Biosciences Distribution B.V.
Country
Netherlands (NL)
ATC code
D11AH09
ATC class
Ruxolitinib
Defined daily dose
30 mg, T
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1726

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Ruxolitinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ruxolitinib products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Polink, Ruxib
  • Bulgaria · Руджави, Руксолитиниб Сандоз
  • Cyprus · Ruxolitinib Sandoz
  • Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
  • Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
  • Estonia · Ruxolitinib Msn
  • Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
  • Finland · Ruxolitinib Orion
  • France · Ruxolitinib Biogaran, Ruxolitinib Olpha
  • United Kingdom (Northern Ireland) · Ruxolitinib Msn Laboratories Europe, Ruxolitinib Torrent
  • Greece · Jakulya
  • Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
  • Hungary · Ruxolitinib Sandoz
  • Iceland · Jakavi, Jakulya
  • Italy · Ruxolitinib Vivanta
  • Liechtenstein · Jakavi, Opzelura
  • Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
  • Latvia · Ruxolitinib Msn
  • Malta · Donlize, Ruxolitinib Medichem
  • Norway · Jakavi, Opzelura
  • Romania · Ruxolitinib Msn
  • Sweden · Ruxolitinib Devatis, Ruxolitinib Orion

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/af12deb3-ed5d-42a6-afb2-b6a2d00c1cf2
GET /v1/drugs/af12deb3-ed5d-42a6-afb2-b6a2d00c1cf2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Crème",
  "route": "Cutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/opzelura-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ruxolitinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129061",
  "excipients": [
    "BUTYLHYDROXYTOLUEEN (E 321)",
    "CETYLALCOHOL",
    "DIMETICON (E 900)",
    "DINATRIUMEDETAAT 2-WATER",
    "FENOXYETHANOL",
    "GLYCEROLSTEARAAT",
    "KALIUMSTEARAAT",
    "MACROGOL 200",
    "METHYLPARAHYDROXYBENZOAAT (E 218)",
    "PARAFFINE, DUNVLOEIBAAR (E 905)",
    "PARAFFINE, ZACHT (E 905)",
    "POLYSORBAAT 20 (E 432)",
    "PROPYLEENGLYCOL (E 1520)",
    "PROPYLPARAHYDROXYBENZOAAT",
    "STEARYLALCOHOL",
    "TRIGLYCERIDEN MIDDELLANGE KETEN",
    "WATER, GEZUIVERD",
    "XANTHAANGOM (E 415)"
  ],
  "substances": [
    "RUXOLITINIBFOSFAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/04/19",
  "procedure_number": "EMEA/H/C/005843",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1726",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about ruxolitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console